샘플 요청 목록

 카트 문의
시장보고서
상품코드
1646746

세계의 환자 유래 이종이식/PDX 모델 시장

Patient Derived Xenograft / PDX Models
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 310 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

환자 유래 이종이식/PDX 모델 세계 시장, 2030년까지 10억 달러에 달할 전망

2023년에 4억 1,230만 달러로 추정되는 환자 유래 이종이식/PDX 모델 세계 시장은 2030년에는 10억 달러에 달할 것으로 예상되며, 분석 기간인 2023-2030년 동안 연평균 14.2%로 성장할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 마우스 PDX 모델 분야는 CAGR 14.8%를 기록하여 분석 기간 종료 시점에 7억 9,930만 달러에 달할 것으로 예측됩니다. 쥐 PDX 모델 분야의 성장률은 분석 기간 동안 CAGR 12.5%로 추정됩니다.

미국 시장은 2억 380만 달러로 추정, 중국은 CAGR 15.4%로 성장 전망

미국의 환자 유래 이종이식/PDX 모델 시장은 2023년 2억 380만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 8,830만 달러의 시장 규모에 도달할 것으로 예상되며, 분석 기간인 2023-2030년 동안 15.4%의 CAGR을 기록할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 12.5%와 13.8%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 약 13.5%의 CAGR로 성장할 것으로 예상됩니다.

세계 환자 유래 이종이식(PDX) 모델 시장 - 주요 동향 및 촉진요인 요약

PDX 모델은 암 연구와 의약품 개발에 어떤 혁명을 가져오고 있는가?

환자 유래 이종이식(PDX) 모델은 기존의 세포주나 동물 모델에 비해 인간 종양의 생물학을 보다 정확하게 표현할 수 있기 때문에 암 연구 및 신약개발의 강력한 도구로 부상하고 있습니다. 종양을 증식시켜 생체 내에서 연구할 수 있습니다. 이 과정을 통해 암의 거동과 치료 반응을 이해하는 데 중요한 미세 환경과 이질성을 포함한 원래 종양의 유전학적, 조직학적 특징이 유지되며, PDX 모델은 새로운 암 치료법의 효능을 시험할 수 있는 보다 현실적인 플랫폼으로, 연구자들은 종양이 어떻게 진행되고 다른 약물에 반응하는지 어떻게 종양이 진행되고 다른 약물에 반응하는지를 생체 내에서 관찰할 수 있습니다. 이러한 모델은 정밀의료에 필수적인 요소로 환자 맞춤형 치료법을 찾아내어 임상 결과를 개선할 수 있는 희망을 가져다주고 있습니다. 맞춤형 암 치료가 확산됨에 따라 PDX 모델에 대한 수요는 계속 증가하고 있으며, 암 연구에 큰 영향을 미치고 있습니다.

제약 업계가 PDX 모델에 많은 투자를 하는 이유는 무엇일까?

제약 및 바이오 업계에서는 임상시험의 성공률을 높이기 위해 전임상시험에서 환자 유래 이종이식(PDX) 모델을 채택하는 사례가 증가하고 있습니다. 기존의 시험관 내 모델이나 동물 모델은 인간의 종양이 치료에 어떻게 반응할지 정확하게 예측할 수 없는 경우가 많아 임상시험에서 종양 치료제의 높은 실패율의 원인이 되고 있습니다. 반면, PDX 모델은 약물의 효능과 독성을 평가할 수 있는 보다 신뢰할 수 있는 수단을 제공하기 때문에 임상 성공 가능성이 높아집니다. 제약사들은 PDX 모델을 활용하여 보다 효율적인 약물 스크리닝을 수행하고, 시장 진입 시간을 단축하며, 약물 개발 관련 비용을 절감하고 있습니다. 또한, PDX 모델에서 유전체 및 전사체 데이터를 통합하여 임상시험에서 환자 선택 및 계층화를 위한 바이오마커를 식별할 수 있습니다. 이러한 개별화 접근법은 표적 치료와 면역 치료의 정확성을 향상시키고 치료 성공 가능성을 높입니다. 보다 예측 가능한 전임상 모델의 필요성이 증가함에 따라 제약 업계의 PDX 기술에 대한 투자는 가속화될 것으로 예상됩니다.

PDX 모델은 맞춤형 의료와 정밀 종양학을 어떻게 강화할 수 있을까?

PDX 모델은 맞춤의료와 정밀 종양학의 발전에 있어 매우 중요한 역할을 하고 있습니다. PDX 모델은 원래 환자 종양의 생물학적 완전성을 유지함으로써 연구자들이 종양 특이적 약물 반응을 조사하고 개별화된 치료 옵션을 식별할 수 있게 해줍니다. 이는 유전자 변이 및 분자 마커에 따라 환자 결과가 크게 달라지는 암에서 특히 중요합니다. 전임상 연구에서 PDX 모델을 사용하면 과학자들은 환자 개개인에게 맞춤화된 치료를 할 수 있어 치료 성공 가능성을 높일 수 있습니다. 또한, PDX 모델은 병용요법 개발 및 내성 기전 평가에 사용되어 치료 중 또는 재발 시 종양이 어떻게 진행되는지에 대한 인사이트를 제공합니다. 환자별 유전자 프로파일에 맞춘 치료법 개발에 대한 관심이 높아짐에 따라 PDX 모델은 치료 효과를 예측하고, 임상적 의사결정을 유도하며, 정밀 종양학 분야를 발전시키는 데 필수적인 도구가 되고 있습니다.

환자 유래 이종이식(PDX) 모델 시장의 성장을 촉진하는 요인은 무엇인가?

환자 유래 이종이식(PDX) 모델 시장의 성장은 암 연구와 의약품 개발을 재구성하고 있는 몇 가지 요인에 의해 주도되고 있습니다. 유전자 시퀀싱과 분자 프로파일링의 기술 발전으로 PDX 모델의 생성 및 분석 능력이 크게 향상되어 전임상시험에서 예측 가능성과 가치가 높아지고 있습니다. 정밀의료와 맞춤 암 치료에 대한 관심이 높아지면서 PDX 모델이 치료 반응을 평가할 수 있는 보다 정확하고 환자 맞춤형 플랫폼을 제공할 수 있게 된 것도 큰 원동력이 되고 있습니다. 제약사들은 의약품 개발의 효율성을 높이고 기존 임상시험의 높은 실패율을 낮추기 위해 PDX 모델을 채택하고 있습니다. 또한, 전 세계 암 발병률의 증가와 새로운 표적 치료제에 대한 수요 증가는 PDX와 같은 첨단 전임상 모델의 필요성을 더욱 부추기고 있습니다. 또한, 학계, 연구기관, 제약사 간의 공동연구는 PDX 플랫폼의 개발 및 상용화를 가속화하여 시장 성장을 더욱 촉진하고 있습니다. 암 연구를 둘러싼 환경이 계속 진화함에 따라 PDX 모델에 대한 수요는 확대되고, 암 연구와 의약품 개발의 핵심적인 역할을 확고히 할 것으로 예상됩니다.

부문

모델 유형(마우스 PDX 모델, 쥐 PDX 모델), 종양 유형(유방암, 폐암, 전립선암, 췌장암, 기타 종양 유형), 용도(전임상 의약품 개발 용도, 바이오마커 분석 용도, 기타 용도), 최종 용도(제약사/바이오기업 최종 용도, CRO/CDMO 최종 용도, 학계/연구기관 최종 용도) CDMO 최종 용도, 학술/연구기관 최종 용도)

조사 대상 기업 사례(주목 42개사)

  • Abnova Corporation
  • Altogen Labs
  • Aragen Life Sciences
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Creative Animodel
  • Crown Bioscience Inc.
  • EPO Berlin-Buch GmbH
  • InnoSer
  • Inotiv, Inc.
  • Oncodesign Services
  • Shanghai Chempartner Co. Ltd.
  • LIDE Shanghai Biotech, Ltd.
  • The Jackson Laboratory
  • Wuxi AppTec
  • Xenopat
  • Xentech

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

ksm 25.02.14

Global Patient Derived Xenograft / PDX Models Market to Reach US$1.0 Billion by 2030

The global market for Patient Derived Xenograft / PDX Models estimated at US$412.3 Million in the year 2023, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 14.2% over the analysis period 2023-2030. Mice PDX Models, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$799.3 Million by the end of the analysis period. Growth in the Rat PDX Models segment is estimated at 12.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$203.8 Million While China is Forecast to Grow at 15.4% CAGR

The Patient Derived Xenograft / PDX Models market in the U.S. is estimated at US$203.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$88.3 Million by the year 2030 trailing a CAGR of 15.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.5% and 13.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

Global Patient-Derived Xenograft (PDX) Models Market – Key Trends & Drivers Summarized

How Are PDX Models Revolutionizing Cancer Research and Drug Development?

Patient-derived xenograft (PDX) models have emerged as a powerful tool in cancer research and drug development, offering more accurate representations of human tumor biology compared to traditional cell lines and animal models. PDX models are created by implanting human tumor tissues directly into immunodeficient mice, allowing the tumor to grow and be studied in a living organism. This process preserves the genetic and histological characteristics of the original tumor, including its microenvironment and heterogeneity, which are critical for understanding cancer’s behavior and treatment responses. PDX models provide a more realistic platform for testing the efficacy of new cancer therapies, allowing researchers to observe how tumors evolve and react to different drugs in vivo. These models have become essential for precision medicine, enabling the identification of patient-specific treatments and offering hope for improved clinical outcomes. As personalized cancer therapies gain traction, the demand for PDX models continues to rise, significantly impacting oncology research.

Why Is the Pharmaceutical Industry Investing Heavily in PDX Models?

The pharmaceutical and biotechnology industries are increasingly adopting patient-derived xenograft (PDX) models in preclinical studies to enhance the success rate of clinical trials. Traditional in vitro and animal models often fail to accurately predict how a human tumor will respond to a treatment, contributing to the high failure rate of oncology drugs in clinical trials. PDX models, on the other hand, provide a more reliable means of evaluating drug efficacy and toxicity, thus improving the chances of clinical success. Pharmaceutical companies are leveraging PDX models to conduct more efficient drug screening, reduce time to market, and lower the costs associated with drug development. Furthermore, the integration of genomic and transcriptomic data from PDX models allows for the identification of biomarkers that can guide patient selection and stratification in clinical trials. This personalized approach enhances the precision of targeted therapies and immunotherapies, increasing the likelihood of successful treatment outcomes. As the need for more predictive preclinical models grows, the pharmaceutical industry's investment in PDX technology is expected to accelerate.

How Are PDX Models Enhancing Personalized Medicine and Precision Oncology?

PDX models are playing a pivotal role in the advancement of personalized medicine and precision oncology. By maintaining the biological integrity of the original patient tumor, PDX models allow researchers to study tumor-specific drug responses and identify personalized treatment options. This is particularly important in cancers where patient outcomes vary widely depending on genetic mutations and molecular markers. The use of PDX models in preclinical research enables scientists to tailor therapies to individual patients, increasing the likelihood of successful treatment. Additionally, PDX models are being used to develop combination therapies and evaluate resistance mechanisms, offering insights into how tumors may evolve during treatment and relapse. With the rising emphasis on developing therapies that are tailored to the unique genetic profiles of patients, PDX models are becoming indispensable tools for predicting treatment responses, guiding clinical decision-making, and advancing the field of precision oncology.

What Factors Are Driving Growth in the Patient-Derived Xenograft (PDX) Models Market?

The growth in the patient-derived xenograft (PDX) models market is driven by several factors that are reshaping cancer research and drug development. Technological advancements in genetic sequencing and molecular profiling have significantly enhanced the ability to create and analyze PDX models, making them more predictive and valuable in preclinical testing. The increasing focus on precision medicine and personalized cancer therapies is another major driver, as PDX models offer a more accurate and patient-specific platform for evaluating treatment responses. Pharmaceutical companies are adopting PDX models to improve the efficiency of drug development and reduce the high failure rates associated with traditional clinical trials. Furthermore, the rise in cancer incidence worldwide and the growing demand for novel, targeted therapies are fueling the need for advanced preclinical models like PDX. Additionally, collaborations between academic institutions, research organizations, and pharmaceutical companies are accelerating the development and commercialization of PDX platforms, further driving market growth. As the landscape of oncology research continues to evolve, the demand for PDX models is expected to expand, solidifying their role as a cornerstone of cancer research and drug development.

SCOPE OF STUDY:

The report analyzes the Patient Derived Xenograft / PDX Models market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Model Type (Mice PDX Models, Rat PDX Models); Tumor Type (Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Other Tumor Types); Application (Pre-Clinical Drug Development Application, Biomarker Analysis Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Abnova Corporation
  • Altogen Labs
  • Aragen Life Sciences
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories
  • Creative Animodel
  • Crown Bioscience Inc.
  • EPO Berlin-Buch GmbH
  • InnoSer
  • Inotiv, Inc.
  • Oncodesign Services
  • Shanghai Chempartner Co. Ltd.
  • LIDE Shanghai Biotech, Ltd.
  • The Jackson Laboratory
  • Wuxi AppTec
  • Xenopat
  • Xentech

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Rise in Cancer Incidence Fosters Growth in Patient Derived Xenograft / PDX Models Market
    • Select Cancer Statistics
    • EXHIBIT 1: Total Number of New Cancer Cases by Type: 2022
    • EXHIBIT 2: Total Number of Cancer Deaths by Type: 2022
    • EXHIBIT 3: Cancer Incidence by Region: 2022
    • EXHIBIT 4: Cancer Mortality by Region: 2022
    • Evolution & Relevance of PDX Models
    • Establishing PDX Models
    • PDX Models: Key Applications
    • Economic Frontiers: Trends, Trials & Transformations
    • EXHIBIT 5: In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
    • EXHIBIT 6: All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
    • EXHIBIT 7: With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
    • Competitive Scenario
    • EXHIBIT 8: Patient Derived Xenograft / PDX Models - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2024 (E)
    • Global Market Overview and Prospects
    • Patient-Derived Xenograft (PDX) Models to Gain More Ground & Become a Buzz Market
    • Delving into Paradigm Segments of Global Patient-Derived Xenograft Model Market
    • Preclinical Drug Development as Key Application
    • Patient-Derived Xenograft Model Market on the March with Interplay of Dynamic Factors
    • Market Drivers
    • Market Opportunities
    • Market Restraints
    • Market Challenges
    • Developments Trending Big on Global Patient-Derived Xenograft Model Market
    • EXHIBIT 9: Select Recently Announced Scientific Research PDX Models & Biobanks of Different Cancer Types
    • Regional Market Analysis
    • North America Remains at Forefront, while Asia-Pacific Dazzles with Steamy Growth on Global PDX Model Market
    • Market Outlook
    • Recent Market Activity
    • Influencer/Product/Technology Insights
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Patient-Derived Xenograft (PDX) Models Transform Personalized Medicine
    • EXHIBIT 10: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • PDX Models Paving the Way for Targeted Therapies
    • The Surge in Investment for Cancer Research to Propel Market Growth
    • Patient-Derived Xenograft (PDX): A Pulsating Tool in the Cancer Research Arsenal
    • EXHIBIT 11: Cancer Research Funding Scenario (2024): Funding Investments & Grants by Major Entities
    • Harnessing the Power of OMICs Technologies Through PDX Models
    • Advancing Predictive Biomarker Discovery with PDX Models
    • Increased Focus on Drug Resistance Studies in Oncology Spurs Demand for Patient-Derived Xenograft Models
    • PDX Models Advance the Evaluation of Treatment Efficacy and Toxicity
    • Technological Advancements Driving Innovation in PDX Models
    • The Intersection of PDX Models and 3D Printing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Patient Derived Xenograft / PDX Models Market Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Mice PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Mice PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Rat PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Rat PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Tumor Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Other Tumor Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Pre-Clinical Drug Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Pre-Clinical Drug Development Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biomarker Analysis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Biomarker Analysis Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for CROs / CDMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World 7-Year Perspective for CROs / CDMOs End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 29: World 7-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • Market Analytics
    • TABLE 30: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: USA 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: USA 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: USA 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Canada 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Canada 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • JAPAN
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Japan 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Japan 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Japan 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • CHINA
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • Market Analytics
    • TABLE 54: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: China 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: China 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: China 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • EUROPE
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • Market Analytics
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • FRANCE
    • TABLE 72: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: France 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: France 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: France 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • GERMANY
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Germany 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Germany 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • ITALY
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Italy 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Italy 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Italy 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Italy 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • UNITED KINGDOM
    • TABLE 96: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 97: UK 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: UK 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 101: UK 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 103: UK 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • Market Analytics
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model Type - Mice PDX Models and Rat PDX Models - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 121: Rest of World 7-Year Perspective for Patient Derived Xenograft / PDX Models by Model Type - Percentage Breakdown of Value Revenues for Mice PDX Models and Rat PDX Models for the Years 2024 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Tumor Type - Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of World 7-Year Perspective for Patient Derived Xenograft / PDX Models by Tumor Type - Percentage Breakdown of Value Revenues for Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer and Other Tumor Types for the Years 2024 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 125: Rest of World 7-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Revenues for Pre-Clinical Drug Development Application, Biomarker Analysis Application and Other Applications for the Years 2024 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 127: Rest of World 7-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use and Academic & Research Institutes End-Use for the Years 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제